Table 2. The clinicopathological features of patients with or without splenectomy before PSM.
| Clinical variables | Splenectomy (n=49) | Non-splenomegaly (n=91) | P |
|---|---|---|---|
| Age, year | 49.0 (33.0–69.0) | 47.0 (32.0–75.0) | 0.647 |
| Sex | 0.408 | ||
| Male | 46 (93.9%) | 80 (87.9%) | |
| Female | 3 (6.1%) | 11 (12.1%) | |
| Hepatitis B virus infection | 0.983 | ||
| No | 11 (22.4%) | 22 (24.2%) | |
| Yes | 38 (77.6%) | 69 (75.8%) | |
| HBsAg | 0.379 | ||
| No | 3 (6.1%) | 11 (12.1%) | |
| Yes | 46 (93.9%) | 80 (87.9%) | |
| Tumor diameter | 8.0 (1.2–15.0) | 8.0 (0.0–18.0) | 0.252 |
| No# of tumor | 0.916 | ||
| Single | 47 (85.7%) | 80 (87.9%) | |
| Multiple | 2 (14.3%) | 11 (12.1%) | |
| PVTT | 1.000 | ||
| I | 16 (32.7%) | 30 (33.0%) | |
| II | 33 (67.3%) | 61 (67.0%) | |
| Encapsulation | 1.000 | ||
| No | 31 (63.3%) | 56 (61.5%) | |
| Incomplete | 3 (6.1%) | 6 (6.6%) | |
| Complete | 15 (30.6%) | 29 (31.9%) | |
| Liver cirrhosis | 1.000 | ||
| No | 7 (14.3%) | 14 (32.8%) | |
| Yes | 42 (85.7%) | 77 (67.2%) | |
| Ascites | 0.448 | ||
| No | 44 (89.8%) | 76 (83.5%) | |
| Yes | 5 (10.2%) | 15 (16.5%) | |
| Esophageal and gastric varices | 0.565 | ||
| No | 40 (81.6%) | 69 (75.8%) | |
| Yes | 9 (18.4%) | 22 (24.2%) | |
| Child-Pugh | 0.121 | ||
| A | 47 (95.9%) | 91 (100.0%) | |
| B | 2 (4.1%) | 0 (0.0%) | |
| Satellite lesions | 0.827 | ||
| None | 4 (8.2%) | 7 (5.9%) | |
| Same lobe | 42 (85.7%) | 75 (75.0%) | |
| Different lobe | 3 (6.1%) | 9 (19.1%) | |
| Thickness of splenic hilum | 5.0 (4.1–10.0) | 5 (4.1–15.0) | 0.725 |
| TBIL | 15.6 (6.0–29.0) | 14.4 (5.3–32.0) | 0.426 |
| DBIL | 6.0 (3.0–16.0) | 5.9 (2.1–19.0) | 0.426 |
| ALB | 41.0 (30.0–50.0) | 42.0 (30.0–52.0) | 0.538 |
| ALT | 47.0 (18.0–262.0) | 47.0 (11.0–208.0) | 0.603 |
| PT | 12.5 (0.0–112.0) | 12.4 (0.0–15.5) | 0.382 |
| GGT | 122.0 (36.0–1052.0) | 114.0 (0.0–584.0) | 0.108 |
| ALP | 107.0 (60.0–372.0) | 108.0 (46.0–255.0) | 0.104 |
| AFP | 1000.0 (1.0–1210.0) | 1210.0 (0.0–1210.0) | 0.788 |
| CA199 | 15.6 (0.0–91.6) | 21.0 (0.0–235.0) | 0.025 |
| CEA | 2.0 (0.0–7.2) | 2.0 (0.0–12.0) | 0.235 |
| AST | 41.0 (17.1–263.0) | 54.0 (14.9–390.0) | 0.022 |
| PLT | 141.0 (42.0–384.0) | 141.0 (40.0–400.0) | 0.202 |
Data were presented as n (%) or medians with interquartile range (IQR). PSM, propensity score matching; HBsAg, Hepatitis B surface antigen; PVTT, portal vein tumor thrombus; TBIL, Total Bilirubin; DBIL, Direct Bilirubin; ALB, Albumin; ALT, Alanine Aminotransferase; PT, Prothrombin time; GGT, γ-Glutamyltransferase; ALP, Alkaline phosphatase; AFP, α-fetoprotein; CA199, Carbohydrate Atigen 19-9; CEA, Carcinoembryonic antigen; AST, Aspartate Aminotransferase; PLT, Platelet.